BeiGene (NASDAQ:BGNE) PT Raised to $236.00

BeiGene (NASDAQ:BGNE - Free Report) had its target price boosted by TD Cowen from $235.00 to $236.00 in a research note issued to investors on Wednesday morning, Benzinga reports. TD Cowen currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Sanford C. Bernstein reduced their target price on shares of BeiGene from $196.00 to $161.00 and set a market perform rating for the company in a research note on Wednesday, March 27th. Bank of America lowered their price objective on BeiGene from $179.30 to $164.30 and set a neutral rating on the stock in a report on Monday, April 8th. JPMorgan Chase & Co. increased their target price on BeiGene from $184.00 to $186.00 and gave the stock an overweight rating in a research note on Tuesday, March 19th. Finally, Guggenheim decreased their price target on BeiGene from $350.00 to $345.00 and set a buy rating on the stock in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $250.13.

BeiGene Stock Performance

Shares of BGNE traded up $5.13 during mid-day trading on Wednesday, reaching $144.12. 215,587 shares of the company's stock were exchanged, compared to its average volume of 257,433. The business's fifty day simple moving average is $154.71 and its 200-day simple moving average is $167.69. BeiGene has a 52-week low of $126.97 and a 52-week high of $266.67. The stock has a market capitalization of $13.78 billion, a PE ratio of -16.87 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09.

BeiGene (NASDAQ:BGNE - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business's revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the company posted ($4.29) earnings per share. On average, equities research analysts expect that BeiGene will post -8.87 earnings per share for the current year.

Insiders Place Their Bets

In other BeiGene news, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the sale, the chief executive officer now owns 12,084 shares in the company, valued at approximately $1,799,186.76. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares in the company, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,781 shares of company stock worth $10,222,381. Insiders own 7.40% of the company's stock.

Institutional Trading of BeiGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Knights of Columbus Asset Advisors LLC boosted its position in shares of BeiGene by 20.5% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company's stock worth $80,000 after acquiring an additional 76 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in shares of BeiGene by 4.8% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 1,704 shares of the company's stock worth $306,000 after buying an additional 78 shares during the last quarter. NewEdge Wealth LLC raised its position in shares of BeiGene by 7.5% in the 4th quarter. NewEdge Wealth LLC now owns 1,612 shares of the company's stock worth $291,000 after buying an additional 112 shares during the period. Vestmark Advisory Solutions Inc. boosted its holdings in BeiGene by 9.5% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 1,601 shares of the company's stock valued at $289,000 after acquiring an additional 139 shares during the last quarter. Finally, Parkwood LLC boosted its holdings in BeiGene by 3.0% in the fourth quarter. Parkwood LLC now owns 6,464 shares of the company's stock valued at $1,166,000 after acquiring an additional 191 shares during the last quarter. Hedge funds and other institutional investors own 48.55% of the company's stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.